gene	chromosome	start	end	applicableMutationType	source	sourceEvent	sourceUrls	studyNctId	studyTitle	studyAcronym	studyGender	countriesOfStudy	treatment	treatmentApproachesDrugClass	treatmentApproachesTherapy	applicableCancerType	applicableDoid	blacklistCancerTypes	level	direction	evidenceUrls
BRAF	7	140453136	140453137	MISSENSE	CKB_TRIAL	600X	NCT1	study1	study1			Netherlands(Rotterdam)	Vemurafenib			Breast cancer	X		A	RESPONSIVE	http
BRAF	7	140453136	140453137	MISSENSE	CKB_EVIDENCE	600X							Vemurafenib			Skin Melanoma	X		A	RESPONSIVE	http
